Author:
Yadon Adam N.,Maharaj Kashmeel,Adamson John H.,Lai Yi-Pin,Sacchettini James C.,Ioerger Thomas R.,Rubin Eric J.,Pym Alexander S.
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference66 articles.
1. World Health Organization. Global Tuberculosis Report 2016. Report No. WHO/HTM/TB/2016.13 (World Health Organization, Geneva, 2016).
2. World Health Organization. Treatment of Tuberculosis Guidlines. Report No. WHO/HTM/TB/2009.420 (World Health Organization, Geneva, 2010).
3. Dawson, R. et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 385, 1738–1747 (2015).
4. Chang, K. C. et al. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis. Antimicrob. Agents Chemother. 56, 5465–5475 (2012).
5. Zumla, A. I. et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect. Dis. 14, 327–340 (2014).
Cited by
90 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献